Teva Pharmaceutical Industries (TEVA) Gains from Investment Securities (2016 - 2025)
Historic Gains from Investment Securities for Teva Pharmaceutical Industries (TEVA) over the last 10 years, with Q4 2025 value amounting to $10.0 million.
- Teva Pharmaceutical Industries' Gains from Investment Securities rose 40000.0% to $10.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $7.0 million, marking a year-over-year increase of 25000.0%. This contributed to the annual value of $5.0 million for FY2025, which is 15000.0% up from last year.
- As of Q4 2025, Teva Pharmaceutical Industries' Gains from Investment Securities stood at $10.0 million, which was up 40000.0% from -$2.0 million recorded in Q3 2025.
- In the past 5 years, Teva Pharmaceutical Industries' Gains from Investment Securities ranged from a high of $547.0 million in Q4 2022 and a low of -$11.0 million during Q4 2023
- Over the past 5 years, Teva Pharmaceutical Industries' median Gains from Investment Securities value was $1.0 million (recorded in 2022), while the average stood at $74.5 million.
- In the last 5 years, Teva Pharmaceutical Industries' Gains from Investment Securities plummeted by 10666.67% in 2021 and then soared by 40000.0% in 2025.
- Over the past 5 years, Teva Pharmaceutical Industries' Gains from Investment Securities (Quarter) stood at $498.0 million in 2021, then increased by 9.84% to $547.0 million in 2022, then plummeted by 102.01% to -$11.0 million in 2023, then surged by 118.18% to $2.0 million in 2024, then soared by 400.0% to $10.0 million in 2025.
- Its Gains from Investment Securities was $10.0 million in Q4 2025, compared to -$2.0 million in Q3 2025 and -$3.0 million in Q2 2025.